# Dose-Escalation Study of SCD-101 in Sickle Cell Disease

> **NCT02380079** · PHASE1 · UNKNOWN · sponsor: **Invenux, LLC** · enrollment: 60 (estimated)

## Conditions studied

- Sickle Cell Disease
- Sickle-Beta Zero Thalassemia

## Interventions

- **DRUG:** SCD-101

## Key facts

- **NCT ID:** NCT02380079
- **Lead sponsor:** Invenux, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-02
- **Primary completion:** 2023-11
- **Final completion:** 2023-12
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2023-03-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02380079

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02380079, "Dose-Escalation Study of SCD-101 in Sickle Cell Disease". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT02380079. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*